1Yanardag H,Tetikkurt C,Bilir M,et al. Diagnosis of cutaneous sarcoidosis;clinical and the prognostic significance of skin lesions[J]. Multidiscip Respir Med,2013,8(1):26.
2Erckens RJ,Mostard RL,Wijnen PA,et al. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis[J]. Graefes Arch Clin Exp Ophthalmol,2012,250(5):713-720.
3Lacomis D. Neurosarcoidosis[J]. Curr Neuropharmacol,2011,9(3):429-436.
4Joseph FG,Scolding NJ. Neurosarcoidosis:a study of 30 new cases[J]. J Neurol Neurosurg Psychiatry,2009,80(3),297-304.
6Baughman RP,Lower EE,Drent M. Inhibitors of tumor necrosis factor(TNF) in sarcoidosis:who,what,and how to use them. Sarcoidosis[J]. Vasc Diffuse Lung Dis,2008,25(2):76-89.
7Baughman RP,Costabel U,du Bois RM. Treatment of sarcoidosis[J]. Clin Chest Med,2008,29(3):533-548.
8Elfferich MD,Nelemans PJ,Ponds RW,et al. Everyday cognitive failure in sarcoidosis:the prevalence and the effect of anti-TNF-alpha treatment[J]. Respiration,2010,80(3):212-219.
9Galor A,Perez VL,Hammel JP,et al. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation[J]. Ophthalmology,2006,113(12):2317-2323.
10Hale S,Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis[J]. Cytokine,2006,33(4):231-237.
二级参考文献205
1ATS, ERS, WASOG. Committee: Statement on sarcoidosis[J]. Am J Respir Crit Care Med, 1999,160:736-755.
2Fite E, Fern6ndez-Figueras MT, Prats R, et al. High prevalence of Mw:obacterium tuberculosis DNA ill biopsies fl'om sarcoidosis pa- tients from Catalonia[J]. Spain, Respiration, 2006,73 (1):20-26.
3Stojsic J, Vucinic-Mihailovic V, Jovanovic D, et al. Evaluation of the role of pathology in the diagnosis and differential diagnosis of pulmonary' and extrapulmanary sarcoidosis[J]. Srp Arh Celok Lek, 2011,139(7-8):481-485.
4Takemoto Y, Sakatani M, Takami S, et al. Association between an- giotensin Ⅱ receptor gene polymort-hisnl and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis[J]. Thorax, 1998,53 (6):459-462.
5Jankowska R, Passowicz-Muszyfiska E, Gonecki M, et al. Soluble interleukin 2 receptor (SIL-2R) in bronchoalveolar lavage fluid (BALF) of patients with sarcoidosis and atopic bronchial asthma[J]. Pneumonol Alergol Pol, 2002,70(7-8):347-352.
6Kobayashi H, Sugimoto C, Kanoh S, et al. BALE' lymphocyte CD 4/8 ratio in a case of sarcoidosis with radiologieal resolution [J]. Nihon Kokyuki Gakkai Zasshi, 2006,44(2):134-138.
7Asada K, Chida K. Prognosis and prognostic factors of sarcoidosis in Japan[J]. Nihon Rinsho, 2002,60(9):1839-1844.
8Rodriguez-Garcla JL, Picazo J, Mira C, et al. Systemic sarcoidosiswith spleen involvement[J]. Postgrad Med J, 2001,77 (906) :265.
10Dr. Michael Marnane,Timothy Lynch,Jaqueline Scott,John Stack,Peter J. Kelly.Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab[J]. Journal of Neurology . 2009 (1)
